Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.

Nine women out of 17 in the vagitocin 400 IU group did not experience the most bothersome symptom after seven weeks of treatment; the corresponding figures were 14 and 13 in the placebo group. The difference in the decrease of the number of women experiencing the most bothersome symptom between the start of treatment and after the seven-week treatment period was highly significant when the results in the vagitocin 400 IU and placebo groups were compared ( p = 0.0089).

also in 132,142 other papers

In the vagitocin 400 IU group, the scores were 2.10 ± 0.73 before and 0.88 ± 1.26 after seven weeks of treatment; this decrease was almost significant ( p = 0.0625).

also in 1,858 other papers